461 related articles for article (PubMed ID: 31261380)
1. Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy.
Koller EJ; Gonzalez De La Cruz E; Machula T; Ibanez KR; Lin WL; Williams T; Riffe CJ; Ryu D; Strang KH; Liu X; Janus C; Golde TE; Dickson D; Giasson BI; Chakrabarty P
Hum Mol Genet; 2019 Oct; 28(19):3255-3269. PubMed ID: 31261380
[TBL] [Abstract][Full Text] [Related]
2. A novel triple repeat mutant tau transgenic model that mimics aspects of pick's disease and fronto-temporal tauopathies.
Rockenstein E; Overk CR; Ubhi K; Mante M; Patrick C; Adame A; Bisquert A; Trejo-Morales M; Spencer B; Masliah E
PLoS One; 2015; 10(3):e0121570. PubMed ID: 25803611
[TBL] [Abstract][Full Text] [Related]
3. Dietary Lycopene Supplementation Improves Cognitive Performances in Tau Transgenic Mice Expressing P301L Mutation via Inhibiting Oxidative Stress and Tau Hyperphosphorylation.
Yu L; Wang W; Pang W; Xiao Z; Jiang Y; Hong Y
J Alzheimers Dis; 2017; 57(2):475-482. PubMed ID: 28269786
[TBL] [Abstract][Full Text] [Related]
4. Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy.
Boekhoorn K; Terwel D; Biemans B; Borghgraef P; Wiegert O; Ramakers GJ; de Vos K; Krugers H; Tomiyama T; Mori H; Joels M; van Leuven F; Lucassen PJ
J Neurosci; 2006 Mar; 26(13):3514-23. PubMed ID: 16571759
[TBL] [Abstract][Full Text] [Related]
5. Genotype-specific differences between mouse CNS stem cell lines expressing frontotemporal dementia mutant or wild type human tau.
Orr ME; Pitstick R; Canine B; Ashe KH; Carlson GA
PLoS One; 2012; 7(6):e39328. PubMed ID: 22723997
[TBL] [Abstract][Full Text] [Related]
6. Frontotemporal Dementia P301L Mutation Potentiates but Is Not Sufficient to Cause the Formation of Cytotoxic Fibrils of Tau.
Wang KW; Zhang G; Kuo MH
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834443
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia.
Seo J; Kritskiy O; Watson LA; Barker SJ; Dey D; Raja WK; Lin YT; Ko T; Cho S; Penney J; Silva MC; Sheridan SD; Lucente D; Gusella JF; Dickerson BC; Haggarty SJ; Tsai LH
J Neurosci; 2017 Oct; 37(41):9917-9924. PubMed ID: 28912154
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal evaluation of Tau-P301L transgenic mice reveals no cognitive impairments at 17 months of age.
Kent BA; Heath CJ; Kim CH; Ahrens R; Fraser PE; St George-Hyslop P; Bussey TJ; Saksida LM
Brain Behav; 2018 Jan; 8(1):e00896. PubMed ID: 29568692
[TBL] [Abstract][Full Text] [Related]
9. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice.
Terwel D; Lasrado R; Snauwaert J; Vandeweert E; Van Haesendonck C; Borghgraef P; Van Leuven F
J Biol Chem; 2005 Feb; 280(5):3963-73. PubMed ID: 15509565
[TBL] [Abstract][Full Text] [Related]
10. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
11. Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease.
Menuet C; Borghgraef P; Matarazzo V; Gielis L; Lajard AM; Voituron N; Gestreau C; Dutschmann M; Van Leuven F; Hilaire G
Respir Physiol Neurobiol; 2011 Sep; 178(2):290-303. PubMed ID: 21763469
[TBL] [Abstract][Full Text] [Related]
12. Accelerated neurodegeneration and neuroinflammation in transgenic mice expressing P301L tau mutant and tau-tubulin kinase 1.
Asai H; Ikezu S; Woodbury ME; Yonemoto GM; Cui L; Ikezu T
Am J Pathol; 2014 Mar; 184(3):808-18. PubMed ID: 24418258
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial model of amyloid β and tau reveals synergy between amyloid deposits and tangle formation.
Koller EJ; Ibanez KR; Vo Q; McFarland KN; Gonzalez De La Cruz E; Zobel L; Williams T; Xu G; Ryu D; Patel P; Giasson BI; Prokop S; Chakrabarty P
Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12779. PubMed ID: 34825397
[TBL] [Abstract][Full Text] [Related]
14. Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies.
McKenzie-Nickson S; Chan J; Perez K; Hung LW; Cheng L; Sedjahtera A; Gunawan L; Adlard PA; Hayne DJ; McInnes LE; Donnelly PS; Finkelstein DI; Hill AF; Barnham KJ
ACS Chem Neurosci; 2018 Nov; 9(11):2731-2740. PubMed ID: 29920069
[TBL] [Abstract][Full Text] [Related]
15. Upper airway dysfunction of Tau-P301L mice correlates with tauopathy in midbrain and ponto-medullary brainstem nuclei.
Dutschmann M; Menuet C; Stettner GM; Gestreau C; Borghgraef P; Devijver H; Gielis L; Hilaire G; Van Leuven F
J Neurosci; 2010 Feb; 30(5):1810-21. PubMed ID: 20130190
[TBL] [Abstract][Full Text] [Related]
16. Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model.
Cook C; Kang SS; Carlomagno Y; Lin WL; Yue M; Kurti A; Shinohara M; Jansen-West K; Perkerson E; Castanedes-Casey M; Rousseau L; Phillips V; Bu G; Dickson DW; Petrucelli L; Fryer JD
Hum Mol Genet; 2015 Nov; 24(21):6198-212. PubMed ID: 26276810
[TBL] [Abstract][Full Text] [Related]
17. Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.
Strang KH; Croft CL; Sorrentino ZA; Chakrabarty P; Golde TE; Giasson BI
J Biol Chem; 2018 Feb; 293(7):2408-2421. PubMed ID: 29259137
[TBL] [Abstract][Full Text] [Related]
18. Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy.
Lim J; Balastik M; Lee TH; Nakamura K; Liou YC; Sun A; Finn G; Pastorino L; Lee VM; Lu KP
J Clin Invest; 2008 May; 118(5):1877-89. PubMed ID: 18431510
[TBL] [Abstract][Full Text] [Related]
19. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).
Ramsden M; Kotilinek L; Forster C; Paulson J; McGowan E; SantaCruz K; Guimaraes A; Yue M; Lewis J; Carlson G; Hutton M; Ashe KH
J Neurosci; 2005 Nov; 25(46):10637-47. PubMed ID: 16291936
[TBL] [Abstract][Full Text] [Related]
20. Tauopathies as clinicopathological entities.
Irwin DJ
Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(0 1):S29-33. PubMed ID: 26382841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
